Alkermes' positive Phase 3 results for its novel antidepressant is serving as a rising tide — a storm surge even — for many biotech companies in the depression space.
A new Jefferies research report features top pharmaceutical picks for the fourth quarter. Any of these top picks make good sense for long-term growth and income portfolios.
The top analyst upgrades, downgrades and initiations seen on Friday morning include Activision Blizzard, Electronic Arts, Transocean, Twitter, Wal-Mart and Yum Brands.
One of the best things for investors to do is look for solid growth potential combined with fair valuations. Sprinkle in dividends and you have a recipe for total return success.
Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward.
The top analyst upgrades, downgrades and initiations seen on Monday morning include Colgate-Palmolive, Gilead Sciences, Navistar, Occidental Petroleum, Pandora Media and Wal-Mart.
Major pharmaceuticals have been under fire in light of the recent Mylan EpiPen pricing fiasco, but now a key research firm is seeing one of these companies in a positive light.
Chris Lange The top analyst upgrades, downgrades and initiations seen on Monday morning include Harley-Davidson, HP, KeyCorp, KLA-Tencor, Netflix, Square and T-Mobile.
The broad markets are continuing to hit all-time highs as the market is shifting gears out of the earnings season. Despite all the positive sentiment in the market, quite a few companies…
Credit Suisse sees the Bristol-Myers Squibb gap with Merck getting even worse, even though it still has robust I-O franchise estimates for Bristol-Myers.
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Accenture, Cognizant Technology Solutions, Fitbit, Oracle, Seagate Technology and Vodafone.
Perhaps the move for a rapid exit by Britain from the European Union (or Brexit) may have been interrupted due to a political murder of M.P. Jo Cox on Thursday. As this…
ASCO has just released the abstracts for its exhibitors ahead of the conference. For investors and analysts, sometimes winners or losers from the meeting can be divined ahead of time by these…
Several big FDA decisions should be coming up in the June quarter for the likes of AstraZeneca and Sarepta Therapeutics.
A pharmaceutical company could face a threat to one of its products for a number of reasons, ranging from an improved formulation to a patent expiry and the opening of the floodgates…
